logo-loader
viewANGLE PLC

ANGLE PLC sees big opportunities in non-invasive prenatal testing

Andrew Newland, chief executive of ANGLE PLC (LON:AGL, OTCQX:ANPCY), tells Proactive London's Andrew Scott its device for detecting the early signs of cancer has shown promise harvesting fetal cells.

Parsortix appeared to score well against existing methods of non-invasive prenatal testing (NIPT).

Specifically, it was able to harvest intact cells, which could then be assessed for abnormalities such Down’s Syndrome.

Quick facts: ANGLE PLC

Price: 66 GBX

AIM:AGL
Market: AIM
Market Cap: £114.02 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of ANGLE PLC named herein, including the promotion by the Company of ANGLE PLC in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

ANGLE PLC submits its flagship Parsortix liquid biopsy diagnostic to the FDA

ANGLE PLC (LON:AGL) (OTCQX:ANPCY) CEO Andrew Newland tells Proactive the company has submitted its patent-protected, flagship Parsortix liquid biopsy diagnostic for clearance to the FDA.  Newland says this is a tremendous opportunity for ANGLE, as he says ANGLE is the first company to...

2 weeks, 6 days ago

2 min read